Announced Fri, 10 Jul · 15:53 IST
Routine SEBI compliance certificate for Q1 FY27 filed with BSE
Compliance View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.8%1-day move
₹1113.50
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-1.8-1.8-2.3+0.5-2.3-3.5————
Up moveDown movePending
AI summary
Jenburkt Pharmaceuticals has submitted a routine compliance certificate under SEBI Regulation 74(5) for the quarter ended 30 June 2026. The company's Registrar and Transfer Agent, Bigshare Services, confirmed that all share dematerialization requests received from depository participants were processed and confirmed within the required 15 day timeline. This is a standard quarterly filing and does not involve any material business event.
Likely market impact
Routine compliance filing. No material impact on shareholders or stock price.